The sFLT1 has a very strong VEGF-A trapping activity (Kd = 1–10 pM); thus, the two major symptoms of PE, hypertension and proteinuria, seem similar to the side effects frequently observed in cancer patients treated with a VEGF-A-neutralizing antibody such as bevacizumab19. The gene discussed is VEGFA; the disease is hypertensive disorder.